Nivolumab and relatlimab-rmbw - Biologic Drug Details

Summary for nivolumab and relatlimab-rmbw

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for nivolumab and relatlimab-rmbw

Mechanism of Action	Lymphocyte Activation Gene-3 Antagonists Programmed Death Receptor-1-directed Antibody Interactions
Established Pharmacologic Class	Lymphocyte Activation Gene-3 Blocker Programmed Death Receptor-1 Blocking Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for nivolumab and relatlimab-rmbw Derived from Patent Text Search

No patents found based on company disclosures

Nivolumab and relatlimab-rmbw Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Nivolumab and Relatlimab-rmbw (Opdualag)

Introduction

The approval of Opdualag, a fixed-dose combination of nivolumab and relatlimab-rmbw, by the U.S. Food and Drug Administration (FDA) in March 2022 marked a significant milestone in the treatment of unresectable or metastatic melanoma. This article delves into the market dynamics and financial trajectory of this innovative biologic drug.

Approval and Clinical Significance

Opdualag is the first LAG-3-blocking antibody to be approved in combination with a PD-1 inhibitor, nivolumab, for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma[1][2][4].

Clinical Efficacy

The approval was based on the Phase 2/3 RELATIVITY-047 trial, which demonstrated that Opdualag significantly improved median progression-free survival (PFS) compared to nivolumab monotherapy. Patients receiving Opdualag had a median PFS of 10.1 months, whereas those receiving nivolumab alone had a median PFS of 4.6 months. The overall response rate (ORR) was also higher in the Opdualag group, at 43% compared to 33% for nivolumab alone[1][4].

Market Impact

Competitive Landscape

The introduction of Opdualag into the market for melanoma treatments has altered the competitive landscape. It offers a new treatment option that combines the benefits of both PD-1 and LAG-3 inhibition, providing a more effective treatment regimen for patients. This combination therapy is poised to compete with other immunotherapies such as nivolumab monotherapy, nivolumab plus ipilimumab, and BRAF and MEK inhibitors[3][4].

Patient Population

Opdualag is indicated for a broad patient population, including adult and pediatric patients 12 years or older with unresectable or metastatic melanoma. This broad indication expands the potential market for the drug, making it a significant player in the melanoma treatment market[2][4].

Financial Trajectory

Pricing and Cost-Effectiveness

Opdualag is administered as a single intravenous infusion, with a recommended dosage of 480 mg of nivolumab and 160 mg of relatlimab every 4 weeks. The cost per 20 mL vial is $8,315, which translates to $16,630 every 28 days. However, the economic analysis suggests that Opdualag may not be cost-effective at a willingness-to-pay (WTP) threshold of $50,000 per quality-adjusted life-year (QALY) gained. The incremental cost-effectiveness ratio (ICER) compared to nivolumab-ipilimumab is high, at $610,904 per QALY gained[3].

Revenue Projections

Despite the high cost, Opdualag's clinical efficacy and the growing demand for effective melanoma treatments are expected to drive significant revenue. The drug's ability to offer improved PFS and a potential survival benefit positions it as a valuable option for patients and healthcare providers, which could lead to substantial market share and revenue growth.

Economic Evaluation

The economic evaluation by CADTH found that while Opdualag offers a clinically meaningful benefit in terms of PFS, the evidence for an overall survival (OS) benefit is inconclusive. However, the drug's effectiveness relative to other immunotherapies, such as ipilimumab and pembrolizumab, suggests it could be a preferred option in certain scenarios. The economic model indicates that Opdualag would need a price reduction to be considered cost-effective at common WTP thresholds[3].

Regulatory and Reimbursement Landscape

FDA Approval

The FDA approval of Opdualag was a critical milestone, opening up the U.S. market for this combination therapy. This approval is expected to influence regulatory decisions in other countries, potentially expanding the global market for the drug[1][2].

Reimbursement Considerations

The reimbursement landscape for Opdualag will be crucial in determining its market success. Given the high cost and the need for it to be cost-effective, negotiations with payers and health authorities will be essential. The drug's inclusion in formularies and reimbursement lists will significantly impact its adoption and revenue generation[3].

Patient and Clinician Perspectives

Treatment Preferences

Clinicians and patients are likely to favor Opdualag due to its improved efficacy over nivolumab monotherapy. The combination therapy offers a more robust immune response, which can lead to better treatment outcomes. Patient preferences for treatments with higher response rates and longer PFS will drive demand for Opdualag[4].

Side Effects and Tolerability

The tolerability of Opdualag is another critical factor. The combination of nivolumab and relatlimab has shown to be generally well-tolerated, with side effects consistent with those expected from immunotherapy. This tolerability profile supports its use as a primary treatment option for advanced melanoma[1][4].

Future Outlook

Ongoing Research and Trials

Ongoing and future clinical trials will continue to shape the market dynamics for Opdualag. Further data on overall survival and long-term efficacy will be crucial in solidifying its position in the treatment landscape. Additionally, exploring Opdualag in other cancer types could expand its market potential[4].

Market Competition

The melanoma treatment market is highly competitive, with several immunotherapies and targeted therapies available. Opdualag's success will depend on its ability to differentiate itself through superior clinical outcomes and favorable reimbursement policies. Continuous innovation and strategic marketing will be essential in maintaining market share[3][4].

Key Takeaways

• Clinical Efficacy: Opdualag significantly improves PFS and ORR compared to nivolumab monotherapy.
• Market Impact: Opdualag alters the competitive landscape in melanoma treatment, offering a new and effective combination therapy.
• Financial Trajectory: High cost but potential for significant revenue due to clinical efficacy and market demand.
• Regulatory and Reimbursement: FDA approval and reimbursement considerations are critical for market success.
• Patient and Clinician Perspectives: Favorable treatment outcomes and tolerability drive demand.

FAQs

What is Opdualag and how is it used?

Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the PD-1 inhibitor nivolumab, administered as a single intravenous infusion every 4 weeks for the treatment of unresectable or metastatic melanoma.

What are the key clinical benefits of Opdualag?

Opdualag significantly improves median progression-free survival (PFS) and overall response rate (ORR) compared to nivolumab monotherapy.

Is Opdualag cost-effective?

Opdualag is not considered cost-effective at a willingness-to-pay (WTP) threshold of $50,000 per quality-adjusted life-year (QALY) gained, due to its high cost and the incremental cost-effectiveness ratio (ICER) compared to other treatments.

What is the regulatory status of Opdualag?

Opdualag was approved by the U.S. Food and Drug Administration (FDA) in March 2022 for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

What are the potential future developments for Opdualag?

Ongoing and future clinical trials will provide further data on overall survival and long-term efficacy, and exploring Opdualag in other cancer types could expand its market potential.

Sources

1. Bristol Myers Squibb: U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab-rmbw) as Treatment for Patients with Unresectable or Metastatic Melanoma.
2. FDA: FDA approves Opdualag for unresectable or metastatic melanoma.
3. NCBI: Pharmacoeconomic Review - Nivolumab and Relatlimab (Opdualag).
4. Oncology Live: Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma.